---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-221538"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2025-09-29T23:59:59+00:00"
generated_at: "2026-05-17T05:23:04.508637+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Larimar reports positive nomlabofusp data; all 6-month patients reach carrier-level FXN

## Summary
- 10/10 participants at 6 months achieved skin FXN >50% of healthy volunteer median (asymptomatic carrier levels).
- Directional improvement in mFARS, FARS-ADL, 9-HPT, MFIS vs worsening in natural history cohort after 1 year.
- Anaphylaxis occurred in 7 participants (all within first 6 weeks); starting dose regimen modified; FDA agreed.
- BLA submission seeking accelerated approval for nomlabofusp expected in Q2 2026.

## SEC filing metadata
- accession: 0001193125-25-221538
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2025-09-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000119312525221538/0001193125-25-221538-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000119312525221538/d24800d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-221538
- JSON: https://secwatch.observer/filing/0001193125-25-221538.json
- Plain text: https://secwatch.observer/filing/0001193125-25-221538.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.